Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHAR0003 > Transmitters > Flashcards

Transmitters Flashcards

1
Q

Drugs acting on the CNS increase receptor signalling by:
(3)

A
  1. Increasing availability of NT
    E.g, PD - more pre-cursor supplied (L-DOPA)
    E.g., Depression - metabolism / uptake blocked (SSRIs)
  2. Direct receptor activation
    E.g., Benzodiazepines for anxiety & epilepsy
  3. Act as antagonists
    E.g., Anti-schizophrenic drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why is it hard to target the CNS?

A

CNS has high connectivity - NTs can have actions at many brain sites

Harder to quantify symptoms

Multiple receptors - drugs need to have functional specificity - (e.g., 5-HT has multiple receptors, some excitatory, some inhibitory, therefore inc receptor signalling by increasing [transmitter] may cause multiple effects)

Receptors up- and down-regulate in response to drugs

Crossing BBB - difficult for drugs based on peptides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are CNS disorders caused by EXCESS activity?

A

Chronic pain, epilepsy, anxiety, SCZ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are CNS disorders caused by reduced activity?

A

PD, AD, Depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the cause & treatment of EPILEPSY?

A

Motor disorder caused by uncontrolled neuronal activity due to overactive glutamatergic transmission / reduced GABA function

Treatments:
1. Drugs that block Na+ channels - reducing repetitive neuronal firing
2. Drugs that enhance GABA function (benzodiazepines)
3. Barbiturates (for severe cases) - open Cl- channels causing major inhibition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the cause & treatment of SCZ?

A

Cause: Increased DA function (different to pathways that fail in PD)

Treatment: DA2 receptor antagonist (but too much DA2 antagonism will cause patients to get motor problems like in PD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What type of disorder is anxiety and how do you treat it?

A

Mood disorder triggered by external events

Treatment: benzodiazepines / drugs that increase 5-HT receptor function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the 2 major types of pain?

A

Neuropathic & inflammatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the hall mark sign of PD?

A

Dopaminergic neuronal death of the substantia nigra (nigrostriatal projections) - causing low levels of DA in the basal ganglia

Accumulation of “Lewy Bodies” (alpha synuclein) & tau protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the symptoms of PD?

A

Symptoms: muscle rigidity, akinesia, resting tremor

Early PD = resting tremor & bradykinesia
Late PD = executive function & memory deficits (correlated with appearance of Lewy bodies) as degeneration spreads

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the mainstream treatment of PD?

A

L-DOPA (DA precursor) - can cross the BBB - given with drugs that reduce metabolism of DA & L-DOPA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are examples of late-stage PD treatments?

A

Bromocriptine / Pergolide / Ropinirole - D2 agonists

Apomorphine - D1 & D2 agonist

Amantadine - D1 & D2 & others agonist

Domperidone - peripheral D2 antagonist, given as adjunct

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

The efficacy of L-DOPA in PD treatment depends on what?

A

Surviving neurones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the issues with increasing DA (e.g., in treatment of PD)?

A

DA can be metabolised into NA - causes undesirable effects (e.g., inc HR)

DA acts at several locations - several effects (not specific)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Where does DA act in the brain?

A

Nigrostriatal pathway - inc movement (+ve)
Mesolimbic pathway - liking / wanting / addictive behaviour (-ve)
Mesocortical pathway - psychotic effects - SCZ-like symptoms (-ve)
Pituitary - hormonal effects (prolactin) (-ve)
Chemoreceptor trigger zone - causes vomiting
Periphery - DA responsible for urine regulation - inc DA = dec BP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are adjunct therapies given with L-DOPA to regulate DA metabolism in PD treatment?

A

Carbidopa / Benzerazide - blocks DOPA decarboxylase - doesn’t cross BBB - reduces peripheral side effects

Selegiline - blocks MAO - prevents DA metabolism - inc [DA] in brain

Entacapone - blocks COMT - prevents DA metabolism - inc [DA] in brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are adjunct therapies given with L-DOPA to reduce nausea in PD treatment?

(DA acting at CTZ causes nausea)

A

Carbidopa / Benzerazide - blocks DOPA decarboxylase - dec peripheral DA

Domperidone - blocks signalling in CTZ - doesn’t cross BBB - stops vomiting

18
Q

AD is characterised by what?

A

Extracellular (A-beta) amyloid plaques + intracellular neurofibrillary tangles (tau protein) proceeded by extensive cells death / brain shrinkage

19
Q

What is the cause of AD?

A

Neuronal degeneration - particularly ACh pathways

20
Q

Why can you not use the same treatment strategy as PD in AD (i.e., increasing precursor)?

A

Due to major role of ACh in autonomic & motor systems

21
Q

What are the pre-dementia, early & advanced symptoms of AD?

A

Pre-dementia - short term memory loss & decline in exec function

Early - further decline in short term memory & exec function, some motor deficits (diagnosable here)

Advanced - long-term memory impairment, procedural memories also affected (hallucinations / lose ability to perform basic tasks)

22
Q

What are the treatment strategies for AD?

A

AChE inhibitors (e.g., Donepezil, Rivastigmine, Galantimine)

Memantine

Aducanumab

23
Q

What are the side effects of AChE inhibitors in the treatment of AD?

A

*Symptomatic treatment - very limited therapeutic efficacy + several side effects:
Fatigue, insomnia, hallucinations, muscle cramps

24
Q

What is the mechanism of action of Memantine in AD treatment?

A

NMDA receptor inhibitor
*Mechanisms unclear, limited efficacy + several side effects

25
Q

What is the mechanism of Aducanumab (AD treatment)?

A

Anti-amyloid antibody recently approved
Limited efficacy & side effects (inc. brain swelling & bleeding)

26
Q

What is the treatment strategy for depression?

A

Block of re-uptake / metabolism of NA & 5-HT (MA NTs critical for mood regulation) - to inc synaptic levels

27
Q

Draw the basal ganglia circuitry

A
28
Q

Effect of dopaminergic neuronal death in SN in PD

A

• Neurones from the substantia nigra pars compacta travel to the striatum via the nigrostriatal pathway and can modulate the activity of the indirect pathway through DA release in the striatum. This is thought to inhibit the indirect pathway facilitating movement. This is thought to be one reason by DA depletion in PD can lead to difficulties initiating movement.
• DA increases motor activity by inhibiting the indirect pathway and exciting the direct pathway. In PD many DA neurones lost – less activation of direct pathway + more activation of indirect pathway – tremor may result from reduced D2-mediated inhibition of striatal cholinergic neurones

29
Q

Pain

A

• Acute pain involves activation of nociceptors on peripheral C-fibres – but once tissue damage & inflammation occurs, peripheral actions of prostanoids, bradykinin, 5-HT etc play a major role in sensitisation and activation of C-fibres.
o NSAIDs (aspirin & ibuprofen) act to block actions of prostanoids at injury site
o Local anaesthetics block Na+ channels – reduce firing of pain fibres
• Very brief acute pain is transmitted via AMPA receptors
o If peripheral stimulus continues, peptides released from C-fibres that enable spinal NMDA receptor activation – giving rise to central states of hyperexcitability which are of major importance to many pain states.
• Morphine action the mu opioid receptor (receptor for endogenous opioid peptides), as do most clinically used opioid drugs.

30
Q

What are the Glutamate receptors ?

A

Postsynaptic ionotrophic AMPA & NMDA
Presynaptic ionotrophic Kainate & metabotrophic mGlu(1-8)

31
Q

What is the uptake transporter and elimination mechanism for each of the monoamines?

A

DA - taken up by DAT
NA - taken up by NAT
5-HT - taken up by SERT

All broken down by MAO + COMT

32
Q

How is glutamate synthesised?

A

General metabolism

33
Q

How is GABA synthesised?

A

From glutamate via glutamate decarboxylase

34
Q

How is ACh synthesised?

A

From acetyl coA + choline

35
Q

How is DA synthesised?

A

From tyrosine via tyrosine hydroxylase & dopa decarboxylase

36
Q

How is NA synthesised?

A

From DA by DA-beta-hydroxylase

37
Q

How is 5-HT synthesised?

A

From tryptophan

38
Q

Where is ACh produced?

A

Medial septal nuclei
Basal nucleus of Meynert
Pontemesencephalotegmental complex

39
Q

Where is DA produced?

A

Substantia nigra
Ventral tegmental area

40
Q

Where is NA produced?

A

Locus coeruleus

41
Q

Where is 5-HT produced?

A

Raphe nuclei (in brainstem)

PHAR0003 (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions